SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-008421
Filing Date
2024-05-17
Accepted
2024-05-17 16:25:40
Documents
14
Period of Report
2024-05-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20240517x8k.htm   iXBRL 8-K 36617
  Complete submission text file 0001558370-24-008421.txt   164624

Data Files

Seq Description Document Type Size
2 EX-101.SCH sngx-20240517.xsd EX-101.SCH 4027
3 EX-101.DEF sngx-20240517_def.xml EX-101.DEF 3492
4 EX-101.LAB sngx-20240517_lab.xml EX-101.LAB 17255
5 EX-101.PRE sngx-20240517_pre.xml EX-101.PRE 10059
18 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20240517x8k_htm.xml XML 4842
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

IRS No.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 24960152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)